Implantable Cardioverter Defibrillator Market Size, Share and Trends Analysis | Global | 2025-2032 | Includes: Transvenous ICD, Subcutaneous ICD, and Extravascular ICDs
Description
Global Implantable Cardioverter Defibrillator Market Report
By iData Research - 129 pages - 6 charts, 94 figures
Executive Summary
The global implantable cardioverter defibrillator market was valued at over $3.1 billion in 2025. Over the forecast period, the market is expected to grow at a CAGR of 4.0% to reach approximately $4.08 billion.
The full report suite on the global market for implantable cardioverter defibrillators, or ICDs, includes single-chamber ICDs, dual-chamber ICDs, subcutaneous ICDs and extra-vascular ICDs. This report follows the same structure and sequencing used in the attached example document, adapted to the global ICD market and its specific competitive, technological and procedural dynamics .
This report provides detailed analysis of unit sales, average selling prices, procedure numbers, market size and growth trends, with historical data to 2022 and forward-looking market forecasts across the forecast period. It also includes market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and leading competitors. The result is a focused strategic view of one of the most important therapy categories within cardiac rhythm management.
The ICD market has returned to a stable growth profile supported by consistent guideline reinforcement for both primary and secondary prevention, along with an expanding population of patients with structural heart disease. Across major regions, physicians continue to rely on ICD therapy for long-term protection against sudden cardiac death, which helps maintain steady unit demand. This gives the market a durable clinical foundation even as product innovation and competitive differentiation continue to evolve.
Overall, the global ICD market remains a clinically essential and strategically important segment of the broader CRM industry. It combines a large base of established demand with enough innovation to sustain long-term value growth across both mature and developing regions.
Market Overview
The global implantable cardioverter defibrillator market includes implantable devices used to detect and treat life-threatening ventricular arrhythmias. These devices play a central role in sudden cardiac death prevention by monitoring rhythm continuously and delivering therapy when dangerous tachyarrhythmias occur. In some cases, they also provide pacing support, including antitachycardia pacing, bradycardia pacing or related rhythm management functions depending on the platform.
ICDs remain one of the most important therapies in cardiac rhythm management because they serve patients with a persistent and serious risk profile. This includes patients with prior ventricular arrhythmias, ischemic cardiomyopathy, non-ischemic cardiomyopathy and other forms of structural heart disease that elevate the risk of sudden cardiac death. As guidelines continue reinforcing the role of ICDs in both primary and secondary prevention, the market benefits from a stable and clinically justified base of demand.
The category includes both mature and emerging segments. Traditional transvenous single-chamber and dual-chamber ICDs still account for a large portion of global implants and remain essential in many patient populations. However, the market is increasingly influenced by newer alternatives such as subcutaneous ICDs and extra-vascular ICDs, which are changing physician choice in selected cases by reducing lead-related burden or preserving pacing functionality without requiring standard transvenous lead placement.
Market Drivers
New Technologies
One of the strongest drivers in the global ICD market is technological advancement. Current innovation is centered on smaller device sizes, longer battery longevity, better sensing algorithms and broader wireless connectivity that supports continuous remote follow-up. These upgrades improve device performance while also reducing the replacement burden and helping clinicians manage patients more efficiently over time.
Battery innovation is especially important in ICDs because they consume substantially more power than pacemakers. Improvements in efficiency and thermal stability can extend service life and reduce the frequency of generator replacement procedures. This creates value for both physicians and health systems because longer longevity improves long-term economics and lowers exposure to replacement-related complications.
Device design improvements also continue to support growth. Better housing durability, infection mitigation strategies and stronger lead performance all reinforce confidence in ICD therapy. In a market where reliability is central to purchasing and implant decisions, these features matter greatly.
Growing Diagnostic Coverage
Another key driver is the expansion of arrhythmia detection through broader rhythm surveillance. Wearable sensors, extended ECG monitoring and implantable monitors are helping identify patients with ventricular arrhythmias who might previously have gone undetected. As diagnostic coverage expands, more patients are referred into specialist pathways where ICD therapy becomes an option.
This is important because it broadens the treatable population beyond patients with already obvious arrhythmic events. Earlier or more complete detection supports more consistent referral patterns and strengthens the overall demand base for ICD therapy.
Lead Alternative Systems
Lead alternative systems are also becoming a major source of growth. The EMBLEM S-ICD continues to benefit from strong adoption because it offers defibrillation therapy without transvenous leads, which appeals to physicians seeking to reduce lead-related complications in selected patients. The platform’s established real-world performance and longevity profile continue to support its use in major markets.
Extra-vascular systems add a further layer of momentum. The Aurora EV ICD is significant because it delivers a lead-avoiding approach while still preserving short-duration pacing capability and antitachycardia pacing. This gives it an important advantage in patient groups where the limitations of current subcutaneous systems previously narrowed adoption. As these systems become more familiar and more broadly available, they are helping redefine how physicians think about ICD therapy.
Market Limiters
Device and Lead-Related Recalls Create Immediate Share Volatility
A major limiter in the ICD market is the effect of recalls and safety-related events. High-profile device and lead-related issues can quickly alter hospital purchasing behavior and shift market share between competitors. Even when the direct clinical impact is limited to a subset of devices, these events can affect physician confidence across broader product families.
Recent recall activity has shown how sensitive the category remains to reliability concerns. Safety communications and recall actions can trigger enhanced monitoring, early replacement activity and procurement reassessment, all of which add volatility to near-term market performance. These events also raise regulatory scrutiny across the category, increasing the burden on manufacturers and reinforcing the importance of reliability data in future purchasing decisions.
High Procedural Costs Limit Penetration
Another major limiter is the high total cost of ICD implantation. In developed markets, the cost of a transvenous ICD procedure is substantial, and while reimbursement may support therapy use in many settings, cost still influences how hospitals evaluate device choice and patient access. In developing markets, the problem is more severe because reimbursement coverage may be limited or inconsistent and out-of-pocket burden may be high.
This has a direct effect on penetration in Latin America, the Middle East and Africa, where cardiovascular disease burden is growing but access to premium device therapy remains more constrained. In those settings, the clinical need may be strong, but financial barriers continue to suppress adoption.
Market Maturity in Developed Regions
The ICD market is also limited by maturity in many developed countries. The therapy is already well established, and growth is not coming from a dramatic rise in first-time adoption across all populations. Instead, it comes from a combination of stable implant volume, replacement cycles, technology upgrades and incremental expansion in selected patient groups. This gives the market dependable growth, but not explosive expansion.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.
Qualitative Coverage
Market drivers and limiters, growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.
Time Frame
Base year 2025, historical data to 2022 and forecasts through the report period.
Data Types Included
Unit sales, average selling prices, procedure numbers, market size and growth trends.
This report is designed to support strategic planning, product positioning and competitive benchmarking by combining detailed market sizing with practical analysis of the technological and commercial forces shaping the ICD category.
Markets Covered and Segmentation
The report covers the Global Implantable Cardioverter Defibrillator Market, further segmented into:
Single-Chamber ICD Market
This segment includes standard transvenous ICD systems designed primarily for ventricular sensing and therapy in patients who do not require more complex chamber support.
Dual-Chamber ICD Market
This segment includes systems capable of dual-chamber sensing and pacing functionality, supporting a broader set of rhythm management needs.
Subcutaneous ICD Market
This segment includes lead-free defibrillation platforms placed outside the vasculature, offering an alternative for selected patients where transvenous lead avoidance is desirable.
Extra-Vascular ICD Market
This segment includes newer systems that avoid traditional transvenous lead placement while preserving additional pacing capabilities.
Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts across the report period and historical data to 2022.
Competitive Analysis
Boston Scientific is the global leader in the ICD market, supported by a broad high-voltage portfolio and the most established subcutaneous ICD platform. Its most important competitive advantage comes from its leadership in subcutaneous ICD therapy. The EMBLEM MRI system remains the only widely adopted subcutaneous ICD with deep global clinical validation, giving Boston Scientific a differentiated and defensible position in one of the category’s most important premium segments.
In transvenous ICDs, Boston Scientific’s portfolio includes Dynagen, Dynagen Mini, Inogen and Inogen Mini. These systems offer compact form factors, strong longevity and advanced arrhythmia detection features. Together, they support Boston Scientific’s share across both primary and secondary prevention indications and help maintain strong positioning in major global markets.
Medtronic holds the second-leading position and competes through a broad and consistently updated portfolio that includes Cobalt, Crome, Evera MRI and Visia AF MRI. The company also strengthened its strategic position with the Aurora EV ICD, which gives physicians a lead-avoiding option while preserving pacing capability, including antitachycardia pacing. That feature is especially important because it creates a meaningful distinction relative to already-established subcutaneous systems. Medtronic’s scale, worldwide distribution and strong evidence base continue to reinforce its position.
Abbott remains the stable third-leading competitor in the global market. Its portfolio is led by Gallant, which offers long longevity, advanced diagnostics and Bluetooth-enabled remote monitoring. Entrant supports more value-oriented markets, while Ellipse remains relevant in regions where the platform has longstanding familiarity. Abbott does not currently compete in subcutaneous or extra-vascular ICDs, but it remains competitive in transvenous ICDs through reliability, compact design and integration with its broader CRM ecosystem.
Technology and Practice Trends
One of the most important trends in the ICD market is the rise of lead alternative systems. Subcutaneous ICDs have already established themselves as a meaningful therapy option, and extra-vascular systems are now expanding that concept by preserving additional pacing capability.
Another major trend is better remote monitoring. Modern ICDs increasingly support wireless data transfer and cloud-based follow-up, which improves patient management and strengthens the overall clinical value of therapy.
Battery longevity and sensing quality continue to improve, helping reduce replacement burden and increase physician confidence in long-term device performance.
Finally, the market is moving toward more selective premiumization. Rather than all ICDs being treated as interchangeable, premium segments are increasingly defined by lead strategy, pacing capability, connectivity and long-term economic value.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Deliverables
129 pages of detailed market analysis, segmentation and forecast data.
6 charts and 94 figures covering market performance, regional trends and competitive positioning.
Methodology Appendix and Acronym Glossary.
Licensing options include single-user, site and enterprise.
Why This Report
Where are the strongest opportunities in the global ICD market through the forecast period?
How are subcutaneous and extra-vascular systems changing the future structure of the category?
What role do battery life, remote monitoring and sensing improvements play in competitive differentiation?
How do recalls, high procedural costs and access barriers affect market penetration across regions?
Which competitors are best positioned in transvenous and lead alternative ICD systems?
How can suppliers, investors and strategy teams evaluate long-term opportunity in one of the most important high-voltage CRM markets?
The Global Implantable Cardioverter Defibrillator Market Report from iData Research answers these questions with detailed market sizing, pricing analysis, segmentation and competitive intelligence. Use it to benchmark competitors, understand technology-driven growth and support strategy in a mature but still evolving global ICD market.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
By iData Research - 129 pages - 6 charts, 94 figures
Executive Summary
The global implantable cardioverter defibrillator market was valued at over $3.1 billion in 2025. Over the forecast period, the market is expected to grow at a CAGR of 4.0% to reach approximately $4.08 billion.
The full report suite on the global market for implantable cardioverter defibrillators, or ICDs, includes single-chamber ICDs, dual-chamber ICDs, subcutaneous ICDs and extra-vascular ICDs. This report follows the same structure and sequencing used in the attached example document, adapted to the global ICD market and its specific competitive, technological and procedural dynamics .
This report provides detailed analysis of unit sales, average selling prices, procedure numbers, market size and growth trends, with historical data to 2022 and forward-looking market forecasts across the forecast period. It also includes market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and leading competitors. The result is a focused strategic view of one of the most important therapy categories within cardiac rhythm management.
The ICD market has returned to a stable growth profile supported by consistent guideline reinforcement for both primary and secondary prevention, along with an expanding population of patients with structural heart disease. Across major regions, physicians continue to rely on ICD therapy for long-term protection against sudden cardiac death, which helps maintain steady unit demand. This gives the market a durable clinical foundation even as product innovation and competitive differentiation continue to evolve.
Overall, the global ICD market remains a clinically essential and strategically important segment of the broader CRM industry. It combines a large base of established demand with enough innovation to sustain long-term value growth across both mature and developing regions.
Market Overview
The global implantable cardioverter defibrillator market includes implantable devices used to detect and treat life-threatening ventricular arrhythmias. These devices play a central role in sudden cardiac death prevention by monitoring rhythm continuously and delivering therapy when dangerous tachyarrhythmias occur. In some cases, they also provide pacing support, including antitachycardia pacing, bradycardia pacing or related rhythm management functions depending on the platform.
ICDs remain one of the most important therapies in cardiac rhythm management because they serve patients with a persistent and serious risk profile. This includes patients with prior ventricular arrhythmias, ischemic cardiomyopathy, non-ischemic cardiomyopathy and other forms of structural heart disease that elevate the risk of sudden cardiac death. As guidelines continue reinforcing the role of ICDs in both primary and secondary prevention, the market benefits from a stable and clinically justified base of demand.
The category includes both mature and emerging segments. Traditional transvenous single-chamber and dual-chamber ICDs still account for a large portion of global implants and remain essential in many patient populations. However, the market is increasingly influenced by newer alternatives such as subcutaneous ICDs and extra-vascular ICDs, which are changing physician choice in selected cases by reducing lead-related burden or preserving pacing functionality without requiring standard transvenous lead placement.
Market Drivers
New Technologies
One of the strongest drivers in the global ICD market is technological advancement. Current innovation is centered on smaller device sizes, longer battery longevity, better sensing algorithms and broader wireless connectivity that supports continuous remote follow-up. These upgrades improve device performance while also reducing the replacement burden and helping clinicians manage patients more efficiently over time.
Battery innovation is especially important in ICDs because they consume substantially more power than pacemakers. Improvements in efficiency and thermal stability can extend service life and reduce the frequency of generator replacement procedures. This creates value for both physicians and health systems because longer longevity improves long-term economics and lowers exposure to replacement-related complications.
Device design improvements also continue to support growth. Better housing durability, infection mitigation strategies and stronger lead performance all reinforce confidence in ICD therapy. In a market where reliability is central to purchasing and implant decisions, these features matter greatly.
Growing Diagnostic Coverage
Another key driver is the expansion of arrhythmia detection through broader rhythm surveillance. Wearable sensors, extended ECG monitoring and implantable monitors are helping identify patients with ventricular arrhythmias who might previously have gone undetected. As diagnostic coverage expands, more patients are referred into specialist pathways where ICD therapy becomes an option.
This is important because it broadens the treatable population beyond patients with already obvious arrhythmic events. Earlier or more complete detection supports more consistent referral patterns and strengthens the overall demand base for ICD therapy.
Lead Alternative Systems
Lead alternative systems are also becoming a major source of growth. The EMBLEM S-ICD continues to benefit from strong adoption because it offers defibrillation therapy without transvenous leads, which appeals to physicians seeking to reduce lead-related complications in selected patients. The platform’s established real-world performance and longevity profile continue to support its use in major markets.
Extra-vascular systems add a further layer of momentum. The Aurora EV ICD is significant because it delivers a lead-avoiding approach while still preserving short-duration pacing capability and antitachycardia pacing. This gives it an important advantage in patient groups where the limitations of current subcutaneous systems previously narrowed adoption. As these systems become more familiar and more broadly available, they are helping redefine how physicians think about ICD therapy.
Market Limiters
Device and Lead-Related Recalls Create Immediate Share Volatility
A major limiter in the ICD market is the effect of recalls and safety-related events. High-profile device and lead-related issues can quickly alter hospital purchasing behavior and shift market share between competitors. Even when the direct clinical impact is limited to a subset of devices, these events can affect physician confidence across broader product families.
Recent recall activity has shown how sensitive the category remains to reliability concerns. Safety communications and recall actions can trigger enhanced monitoring, early replacement activity and procurement reassessment, all of which add volatility to near-term market performance. These events also raise regulatory scrutiny across the category, increasing the burden on manufacturers and reinforcing the importance of reliability data in future purchasing decisions.
High Procedural Costs Limit Penetration
Another major limiter is the high total cost of ICD implantation. In developed markets, the cost of a transvenous ICD procedure is substantial, and while reimbursement may support therapy use in many settings, cost still influences how hospitals evaluate device choice and patient access. In developing markets, the problem is more severe because reimbursement coverage may be limited or inconsistent and out-of-pocket burden may be high.
This has a direct effect on penetration in Latin America, the Middle East and Africa, where cardiovascular disease burden is growing but access to premium device therapy remains more constrained. In those settings, the clinical need may be strong, but financial barriers continue to suppress adoption.
Market Maturity in Developed Regions
The ICD market is also limited by maturity in many developed countries. The therapy is already well established, and growth is not coming from a dramatic rise in first-time adoption across all populations. Instead, it comes from a combination of stable implant volume, replacement cycles, technology upgrades and incremental expansion in selected patient groups. This gives the market dependable growth, but not explosive expansion.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.
Qualitative Coverage
Market drivers and limiters, growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.
Time Frame
Base year 2025, historical data to 2022 and forecasts through the report period.
Data Types Included
Unit sales, average selling prices, procedure numbers, market size and growth trends.
This report is designed to support strategic planning, product positioning and competitive benchmarking by combining detailed market sizing with practical analysis of the technological and commercial forces shaping the ICD category.
Markets Covered and Segmentation
The report covers the Global Implantable Cardioverter Defibrillator Market, further segmented into:
Single-Chamber ICD Market
This segment includes standard transvenous ICD systems designed primarily for ventricular sensing and therapy in patients who do not require more complex chamber support.
Dual-Chamber ICD Market
This segment includes systems capable of dual-chamber sensing and pacing functionality, supporting a broader set of rhythm management needs.
Subcutaneous ICD Market
This segment includes lead-free defibrillation platforms placed outside the vasculature, offering an alternative for selected patients where transvenous lead avoidance is desirable.
Extra-Vascular ICD Market
This segment includes newer systems that avoid traditional transvenous lead placement while preserving additional pacing capabilities.
Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts across the report period and historical data to 2022.
Competitive Analysis
Boston Scientific is the global leader in the ICD market, supported by a broad high-voltage portfolio and the most established subcutaneous ICD platform. Its most important competitive advantage comes from its leadership in subcutaneous ICD therapy. The EMBLEM MRI system remains the only widely adopted subcutaneous ICD with deep global clinical validation, giving Boston Scientific a differentiated and defensible position in one of the category’s most important premium segments.
In transvenous ICDs, Boston Scientific’s portfolio includes Dynagen, Dynagen Mini, Inogen and Inogen Mini. These systems offer compact form factors, strong longevity and advanced arrhythmia detection features. Together, they support Boston Scientific’s share across both primary and secondary prevention indications and help maintain strong positioning in major global markets.
Medtronic holds the second-leading position and competes through a broad and consistently updated portfolio that includes Cobalt, Crome, Evera MRI and Visia AF MRI. The company also strengthened its strategic position with the Aurora EV ICD, which gives physicians a lead-avoiding option while preserving pacing capability, including antitachycardia pacing. That feature is especially important because it creates a meaningful distinction relative to already-established subcutaneous systems. Medtronic’s scale, worldwide distribution and strong evidence base continue to reinforce its position.
Abbott remains the stable third-leading competitor in the global market. Its portfolio is led by Gallant, which offers long longevity, advanced diagnostics and Bluetooth-enabled remote monitoring. Entrant supports more value-oriented markets, while Ellipse remains relevant in regions where the platform has longstanding familiarity. Abbott does not currently compete in subcutaneous or extra-vascular ICDs, but it remains competitive in transvenous ICDs through reliability, compact design and integration with its broader CRM ecosystem.
Technology and Practice Trends
One of the most important trends in the ICD market is the rise of lead alternative systems. Subcutaneous ICDs have already established themselves as a meaningful therapy option, and extra-vascular systems are now expanding that concept by preserving additional pacing capability.
Another major trend is better remote monitoring. Modern ICDs increasingly support wireless data transfer and cloud-based follow-up, which improves patient management and strengthens the overall clinical value of therapy.
Battery longevity and sensing quality continue to improve, helping reduce replacement burden and increase physician confidence in long-term device performance.
Finally, the market is moving toward more selective premiumization. Rather than all ICDs being treated as interchangeable, premium segments are increasingly defined by lead strategy, pacing capability, connectivity and long-term economic value.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Deliverables
129 pages of detailed market analysis, segmentation and forecast data.
6 charts and 94 figures covering market performance, regional trends and competitive positioning.
Methodology Appendix and Acronym Glossary.
Licensing options include single-user, site and enterprise.
Why This Report
Where are the strongest opportunities in the global ICD market through the forecast period?
How are subcutaneous and extra-vascular systems changing the future structure of the category?
What role do battery life, remote monitoring and sensing improvements play in competitive differentiation?
How do recalls, high procedural costs and access barriers affect market penetration across regions?
Which competitors are best positioned in transvenous and lead alternative ICD systems?
How can suppliers, investors and strategy teams evaluate long-term opportunity in one of the most important high-voltage CRM markets?
The Global Implantable Cardioverter Defibrillator Market Report from iData Research answers these questions with detailed market sizing, pricing analysis, segmentation and competitive intelligence. Use it to benchmark competitors, understand technology-driven growth and support strategy in a mature but still evolving global ICD market.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Table of Contents
129 Pages
- List Of Figures
- List Of Charts
- Research Methodology
- Step 1: Project Initiation & Team Selection
- Step 2: Prepare Data Systems And Perform Secondary Research
- Step 3: Preparation For Interviews & Questionnaire Design
- Step 4: Performing Primary Research
- Step 5: Research Analysis: Establishing Baseline Estimates
- Step 6: Market Forecast And Analysis
- Step 7: Identify Strategic Opportunities
- Step 8: Final Review And Market Release
- Step 9: Customer Feedback And Market Monitoring
- Impact Of Global Tariffs
- Implantable Cardioverter Defibrillator Market
- Executive Summary
- 5.1.1 Global Implantable Cardioverter Defibrillator Market Overview
- 5.1.2 Competitive Analysis
- 5.1.3 Procedure Segmentation
- 5.1.4 Market Segmentation
- 5.1.5 Regions Included
- Introduction
- Procedure Numbers
- 5.1.6 Total Icd Placement Procedures
- 5.1.7 Initial Placement Icd Procedures
- 5.1.8 Replacement Icd Procedures
- Market Overview
- 5.1.9 By Segment
- 5.1.1 By Region
- Market Analysis And Forecast
- 5.1.2 Total Icd Market
- 5.1.1 Single-Chamber Icd Market
- 5.1.1.1 Initial Placement Single-Chamber Icd Market
- 5.1.1.2 Replacement Single-Chamber Icd Market
- 5.1.1 Dual-Chamber Icd Market
- 5.1.1.1 Initial Placement Dual-Chamber Icd Market
- 5.1.1.2 Replacement Dual-Chamber Icd Market
- 5.1.1 S-Icd Market
- 5.1.1.1 Initial Placement S-Icd Market
- 5.1.1.2 Replacement S-Icd Market
- 5.1.2 Ev-Icd Market
- Drivers And Limiters
- 5.1.3 Market Drivers
- 5.1.4 Market Limiters
- Competitive Market Share Analysis
- Abbreviations
- Chart 5-1: Implantable Cardioverter Defibrillator Market, Global, 2025 & 2032
- Chart 5-2: Implantable Cardioverter Defibrillator Placement Procedures, Global, 2025
- Chart 5-3: ICD Placement Procedures by Segment, Global, 2022 – 2032
- Chart 5-4: ICD Market by Segment, Global, 2022 – 2032
- Chart 5-5: ICD Market by Region, Global, 2022 – 2032
- Chart 5-6: Leading Competitors, ICD Market, Global, 2025
- Figure 5-1: Implantable Cardioverter Defibrillator Procedure Segmentation
- Figure 5-2: Implantable Cardioverter Defibrillator Market Segmentation
- Figure 5-3: Implantable Cardioverter Defibrillator Regions Covered, Global (1 of 2)
- Figure 5-4: Inferior Vena Cava Filter Regions Covered, Global (2 of 2)
- Figure 5-5: ICD Placement Procedures by Segment, Global, 2022 – 2032
- Figure 5-6: ICD Placement Procedures by Region, Global, 2022 – 2032
- Figure 5-7: ICD Placement Procedures by Country, North America, 2022 – 2032
- Figure 5-8: ICD Placement Procedures by Country, Latin America, 2022 – 2032 (1 of 2)
- Figure 5-9: ICD Placement Procedures by Country, Latin America, 2022 – 2032 (2 of 2)
- Figure 5-10: ICD Placement Procedures by Country, Western Europe, 2022 – 2032
- Figure 5-11: ICD Placement Procedures by Country, Central & Eastern Europe, 2022 – 2032 (1 of 2)
- Figure 5-12: ICD Placement Procedures by Country, Central & Eastern Europe, 2022 – 2032 (2 of 2)
- Figure 5-13: ICD Placement Procedures by Country, Middle East, 2022 – 2032
- Figure 5-14: ICD Placement Procedures by Country, Asia-Pacific, 2022 – 2032 (1 of 3)
- Figure 5-15: ICD Placement Procedures by Country, Asia-Pacific, 2022 – 2032 (2 of 3)
- Figure 5-16: ICD Placement Procedures by Country, Asia-Pacific, 2022 – 2032 (3 of 3)
- Figure 5-17: ICD Placement Procedures by Country, Africa, 2022 – 2032
- Figure 5-18: Initial Placement ICD Procedures by Region, Global, 2022 – 2032
- Figure 5-19: Initial Placement ICD Procedures by Country, North America, 2022 – 2032
- Figure 5-20: Initial Placement ICD Procedures by Country, Latin America, 2022 – 2032 (1 of 2)
- Figure 5-21: Initial Placement ICD Procedures by Country, Latin America, 2022 – 2032 (2 of 2)
- Figure 5-22: Initial Placement ICD Procedures by Country, Western Europe, 2022 – 2032
- Figure 5-23: Initial Placement ICD Procedures by Country, Central & Eastern Europe, 2022 – 2032 (1 of 2)
- Figure 5-24: Initial Placement ICD Procedures by Country, Central & Eastern Europe, 2022 – 2032 (2 of 2)
- Figure 5-25: Initial Placement ICD Procedures by Country, Middle East, 2022 – 2032
- Figure 5-26: Initial Placement ICD Procedures by Country, Asia-Pacific, 2022 – 2032 (1 of 3)
- Figure 5-27: Initial Placement ICD Procedures by Country, Asia-Pacific, 2022 – 2032 (2 of 3)
- Figure 5-28: Initial Placement ICD Procedures by Country, Asia-Pacific, 2022 – 2032 (3 of 3)
- Figure 5-29: Initial Placement ICD Procedures by Country, Africa, 2022 – 2032
- Figure 5-30: Replacement ICD Procedures by Region, Global, 2022 – 2032
- Figure 5-31: Replacement ICD Procedures by Country, North America, 2022 – 2032
- Figure 5-32: Replacement ICD Procedures by Country, Latin America, 2022 – 2032 (1 of 2)
- Figure 5-33: Replacement ICD Procedures by Country, Latin America, 2022 – 2032 (2 of 2)
- Figure 5-34: Replacement ICD Procedures by Country, Western Europe, 2022 – 2032
- Figure 5-35: Replacement ICD Procedures by Country, Central & Eastern Europe, 2022 – 2032 (1 of 2)
- Figure 5-36: Replacement ICD Procedures by Country, Central & Eastern Europe, 2022 – 2032 (2 of 2)
- Figure 5-37: Replacement ICD Procedures by Country, Middle East, 2022 – 2032
- Figure 5-38: Replacement ICD Procedures by Country, Asia-Pacific, 2022 – 2032 (1 of 3)
- Figure 5-39: Replacement ICD Procedures by Country, Asia-Pacific, 2022 – 2032 (2 of 3)
- Figure 5-40: Replacement ICD Procedures by Country, Asia-Pacific, 2022 – 2032 (3 of 3)
- Figure 5-41: Replacement ICD Procedures by Country, Africa, 2022 – 2032
- Figure 5-42: ICD Market by Segment, Global, 2022 – 2032 (US$M)
- Figure 5-43: ICD Market by Region, Global, 2022 – 2032 (US$M)
- Figure 5-44: ICD Market, Global, 2022 – 2032
- Figure 5-45: Units Sold by Region, ICD Market, Global, 2022 – 2032
- Figure 5-46: Average Selling Price by Region, ICD Market, Global, 2022 – 2032 (US$)
- Figure 5-47: Market Value by Region, ICD Market, Global, 2022 – 2032 (US$M)
- Figure 5-48: Single-Chamber ICD Market by Segment, Global, 2022 – 2032 (US$M)
- Figure 5-49: Single-Chamber ICD Market, Global, 2022 – 2032
- Figure 5-50: Units Sold by Region, Single-Chamber ICD Market, Global, 2022 – 2032
- Figure 5-51: Average Selling Price by Region, Single-Chamber ICD Market, Global, 2022 – 2032 (US$)
- Figure 5-52: Market Value by Region, Single-Chamber ICD Market, Global, 2022 – 2032 (US$M)
- Figure 5-53: Initial Placement Single-Chamber ICD Market, Global, 2022 – 2032
- Figure 5-54: Units Sold by Region, Initial Placement Single-Chamber ICD Market, Global, 2022 – 2032
- Figure 5-55: Average Selling Price by Region, Initial Placement Single-Chamber ICD Market, Global, 2022 – 2032 (US$)
- Figure 5-56: Market Value by Region, Initial Placement Single-Chamber ICD Market, Global, 2022 – 2032 (US$M)
- Figure 5-57: Replacement Single-Chamber ICD Market, Global, 2022 – 2032
- Figure 5-58: Units Sold by Region, Replacement Single-Chamber ICD Market, Global, 2022 – 2032
- Figure 5-59: Average Selling Price by Region, Replacement Single-Chamber ICD Market, Global, 2022 – 2032 (US$)
- Figure 5-60: Market Value by Region, Replacement Single-Chamber ICD Market, Global, 2022 – 2032 (US$M)
- Figure 5-61: Dual-Chamber ICD Market by Segment, Global, 2022 – 2032 (US$M)
- Figure 5-62: Dual-Chamber ICD Market, Global, 2022 – 2032
- Figure 5-63: Units Sold by Region, Dual-Chamber ICD Market, Global, 2022 – 2032
- Figure 5-64: Average Selling Price by Region, Dual-Chamber ICD Market, Global, 2022 – 2032 (US$)
- Figure 5-65: Market Value by Region, Dual-Chamber ICD Market, Global, 2022 – 2032 (US$M)
- Figure 5-66: Initial Placement Dual-Chamber ICD Market, Global, 2022 – 2032
- Figure 5-67: Units Sold by Region, Initial Placement Dual-Chamber ICD Market, Global, 2022 – 2032
- Figure 5-68: Average Selling Price by Region, Initial Placement Dual-Chamber ICD Market, Global, 2022 – 2032 (US$)
- Figure 5-69: Market Value by Region, Initial Placement Dual-Chamber ICD Market, Global, 2022 – 2032 (US$M)
- Figure 5-70: Replacement Dual-Chamber ICD Market, Global, 2022 – 2032
- Figure 5-71: Units Sold by Region, Replacement Dual-Chamber ICD Market, Global, 2022 – 2032
- Figure 5-72: Average Selling Price by Region, Replacement Dual-Chamber ICD Market, Global, 2022 – 2032 (US$)
- Figure 5-73: Market Value by Region, Replacement Dual-Chamber ICD Market, Global, 2022 – 2032 (US$M)
- Figure 5-74: S-ICD Market by Segment, Global, 2022 – 2032 (US$M)
- Figure 5-75: S-ICD Market, Global, 2022 – 2032
- Figure 5-76: Units Sold by Region, S-ICD Market, Global, 2022 – 2032
- Figure 5-77: Average Selling Price by Region, S-ICD Market, Global, 2022 – 2032 (US$)
- Figure 5-78: Market Value by Region, S-ICD Market, Global, 2022 – 2032 (US$M)
- Figure 5-79: Initial Placement S-ICD Market, Global, 2022 – 2032
- Figure 5-80: Units Sold by Region, Initial Placement S-ICD Market, Global, 2022 – 2032
- Figure 5-81: Average Selling Price by Region, Initial Placement S-ICD Market, Global, 2022 – 2032 (US$)
- Figure 5-82: Market Value by Region, Initial Placement S-ICD Market, Global, 2022 – 2032 (US$M)
- Figure 5-83: Replacement S-ICD Market, Global, 2022 – 2032
- Figure 5-84: Units Sold by Region, Replacement S-ICD Market, Global, 2022 – 2032
- Figure 5-85: Average Selling Price by Region, Replacement S-ICD Market, Global, 2022 – 2032 (US$)
- Figure 5-86: Market Value by Region, Replacement S-ICD Market, Global, 2022 – 2032 (US$M)
- Figure 5-87: EV-ICD Market, Global, 2022 – 2032
- Figure 5-88: Units Sold by Region, EV-ICD Market, Global, 2022 – 2032
- Figure 5-89: Average Selling Price by Region, EV-ICD Market, Global, 2022 – 2032 (US$)
- Figure 5-90: Market Value by Region, EV-ICD Market, Global, 2022 – 2032 (US$M)
- Figure 5-91: Leading Competitors, ICD Market, Global, 2025
- Figure 5-92: Leading Competitors by Region, ICD Market, Global, 2025
- Figure 5-93: Leading Competitors by Region, Single-Chamber ICD Market, Global, 2025
- Figure 5-94: Leading Competitors by Region, Dual-Chamber ICD Market, Global, 2025
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
